<DOC>
	<DOC>NCT01793688</DOC>
	<brief_summary>The purpose of the survey is to study the followings under practical use, regarding the safety and effectiveness in high-dose administration (exceeding 6 g per day) of UNASYN-S and UNASYN-S KIT for intravenous use (UNASYN). 1. Adverse Drug Reaction(s) that cannot be expected from precautions (Unexpected Adverse Drug Reaction) 2. Incidence status of adverse drug reactions 3. Factors that may affect the safety and effectiveness</brief_summary>
	<brief_title>Drug Use Investigation Of Sulbactam/Ampicillin (UNASYN) 12g (Regulatory Post Marketing Commitment Plan)</brief_title>
	<detailed_description>Implemented as a Special Investigation by a central registration system</detailed_description>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Peritonitis</mesh_term>
	<mesh_term>Lung Abscess</mesh_term>
	<mesh_term>Sulbactam</mesh_term>
	<mesh_term>Ampicillin</mesh_term>
	<mesh_term>Sultamicillin</mesh_term>
	<criteria>Patients with the following disease who received high doses of UNASYN (exceeding 6 g per day) from the first dosing date or the second dosing date. 1) Pneumonia, 2) Lung Abscess, 3) Peritonitis Patients aged 15 years or olde Patients with the following disease who received high doses of UNASYN (less than 6 g per day) from the first dosing date or the second dosing date. 1) Pneumonia, 2) Lung Abscess, 3) Peritonitis Patients aged less than 15 years.</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>UNASYN-S</keyword>
	<keyword>High Dose</keyword>
</DOC>